

Client Information (required)

Client Name		
Client Account No.		
Client Phone	Client Order No.	
Street Address		
City	State	ZIP Code

Submitting Provider Information (required)

Submitting/Referring Provider Name (Last, First)
--

Fill in only if Call Back is required.

Phone (with area code)	Fax* (with area code)
Provider's National I.D. (NPI)	

*Fax number given must be from a fax machine that complies with applicable HIPAA regulation.

Pathologist Information (required)

Submitting/Referring Pathologist Name (Last, First)	
Phone (with area code)	Fax* (with area code)
National Provider Identification (NPI)	

*Fax number given must be from a fax machine that complies with applicable HIPAA regulation.

New York State Patients: Informed Consent for Genetic Testing

"I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office."

Signature

Note: It is the client's responsibility to maintain documentation of the order.

MCL Internal Use Only

Ship specimens to:

Mayo Clinic Laboratories
3050 Superior Drive NW
Rochester, MN 55901

Customer Service: 800-533-1710

Visit www.MayoClinicLabs.com for the most up-to-date test and shipping information.

Patient Information (required)

Patient ID (Medical Record No.)	
Patient Name (Last, First, Middle)	
Sex <input type="checkbox"/> Male <input type="checkbox"/> Female	Birth Date (mm-dd-yyyy)
Collection Date (mm-dd-yyyy)	Time <input type="checkbox"/> am <input type="checkbox"/> pm

Specimens Provided (required)

<input type="checkbox"/> Blood <input type="checkbox"/> Bone marrow <input type="checkbox"/> Fixed cells <input type="checkbox"/> Cultured cells <input type="checkbox"/> DNA <input type="checkbox"/> Lymph node <input type="checkbox"/> Spleen	<input type="checkbox"/> Paraffin block No. sent: _____ Indicate source: _____ _____ <input type="checkbox"/> Slides No. sent: _____	<input type="checkbox"/> Tissue No. sent: _____ <input type="checkbox"/> Frozen <input type="checkbox"/> Fixed formalin <input type="checkbox"/> Wet tissue <input type="checkbox"/> Other fixative Type: _____ <input type="checkbox"/> Other Anatomic site: _____
---	--	---

CBC Results

HB: _____ RBC: _____ WBC: _____
 HCT: _____ MCV: _____ PLT: _____

If ordering HER2 testing:

Was specimen fixed in 10% neutral buffered formalin within 1 hour of surgical collection time? Yes No
 Has specimen been fixed in 10% neutral buffered formalin for 6 to 72 hours? Yes No

Pathology/Clinical Diagnosis (required)

<p>Include a brief history, pertinent laboratory results, suspected diagnosis, and reason for referral.</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p>
ICD-10 Diagnosis Code

Billing Information

- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing-related questions:
800-447-6424 (US and Canada)
507-266-5490 (outside the US)

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (<i>Last, First, Middle</i>)	Client Order No.
Birth Date (<i>mm-dd-yyyy</i>)	

FEATURED ONCOLOGY TESTING

<p>PD-L1 Immunohistochemical stains</p> <p><input type="checkbox"/> 22C3 Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual</p> <p><input type="checkbox"/> 288PD Programmed Death-Ligand 1 (PD-L1) (28-8), Semi-Quantitative Immunohistochemistry, Manual</p> <p><input type="checkbox"/> SP142 Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual</p> <p><input type="checkbox"/> SP263 Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual</p> <p>Microsatellite Instability (MSI)/Mismatch Repair</p> <p><input type="checkbox"/> TMSI Microsatellite Instability, Tumor</p> <p><input type="checkbox"/> IHC Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor</p> <p>Pan-Cancer Biomarkers</p> <p><input type="checkbox"/> NTRK NTRK Gene Fusion Panel, Tumor</p> <p><input type="checkbox"/> BRAFD BRAF V600E/V600K Somatic Mutation Analysis, Tumor</p>	<p>Next-Generation Sequencing (NGS) Panels</p> <p><input type="checkbox"/> MCCRC MayoComplete Colorectal Cancer Panel, Next-Generation Sequencing, Tumor</p> <p><input type="checkbox"/> MCSRC MayoComplete Comprehensive Sarcoma Panel, Next-Generation Sequencing, Tumor</p> <p><input type="checkbox"/> MCGST MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor</p> <p><input type="checkbox"/> MCLNG MayoComplete Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor</p> <p><input type="checkbox"/> MCMLN MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor</p> <p><input type="checkbox"/> MCSTP MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor</p> <p><input type="checkbox"/> NONCP Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor</p> <p><input type="checkbox"/> SARCP Sarcoma Targeted Gene Fusion/Rearrangement Panel, Next-Generation Sequencing, Tumor</p>	<p>Chromosomal Microarray</p> <p><input type="checkbox"/> CMAPT Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded</p> <p>Cell-Free DNA (cfDNA) Testing</p> <p><input type="checkbox"/> BRAFB Cell-Free DNA BRAF V600 Test, Blood</p> <p><input type="checkbox"/> T790M Cell-Free DNA EGFR T790M Mutation Analysis, Blood</p> <p><input type="checkbox"/> KRASD Cell-Free DNA KRAS 12, 13, 61, 146, Blood</p> <p><input type="checkbox"/> MCLBP MayoComplete Liquid Biopsy Panel, Next-Generation Sequencing, Cell-Free DNA</p>
---	--	--

PATHOLOGY

PATHC Pathology Consultation
Appropriate stains and ancillary testing may be performed in order to render an accurate diagnosis

PATHOLOGY: TARGETED TUMOR TESTING

Bone and Soft Tissue

FOXOF Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue

ETV6F ETV6 (12p13.2) Rearrangement, FISH, Tissue

TFE3F Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue

MASF Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue

CTNBT B-Catenin Mutations Analysis, Next-Generation Sequencing, Tumor

ESTUF Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue

EWSF Ewing Sarcoma (EWS), 22q12 (EWSR1) Rearrangement, FISH, Tissue

IMTF Inflammatory Myofibroblastic Tumors (IMT), 2p23 (ALK) Rearrangement, FISH, Tissue

MDM2F MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue

DDITF Myxoid/Round Cell Liposarcoma, 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue

PDGF PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue

SS18F Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue

USPF USP6 (17p13), Aneurysmal Bone Cyst and Nodular Fasciitis, FISH, Tissue

Breast

MASF Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue

BRCAT BRCA1/2 Mutation Analysis, Next-Generation Sequencing, Tumor

PIK3B Cell-Free DNA PIK3CA Test, Blood

ESR1T ESR1 Mutations Analysis, Next-Generation Sequencing, Tumor

FGF1F FGFR1 (8p11.2) Amplification, FISH, Tissue

H2BR HER2 Amplification Associated with Breast Cancer, FISH, Tissue

ESR1T ESR1 Mutations Analysis, Next-Generation Sequencing, Tumor

ETV6F ETV6 (12p13.2) Rearrangement, FISH, Tissue

PIK3T PIK3CA Mutation Analysis, Tumor

Immunohistochemical assays interpreted with digital image analysis

ERPR Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual

KI67B Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated

HERBA HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex

HERBN HER2, Breast, Quantitative Immunohistochemistry, Automated, No Reflex

HERDM HER2, Breast, DCIS, Quantitative Immunohistochemistry, Manual with HER2 FISH Reflex

HERDN HER2, Breast, DCIS, Quantitative Immunohistochemistry, Manual No Reflex

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (<i>Last, First, Middle</i>)	Client Order No.
Birth Date (<i>mm-dd-yyyy</i>)	

Gastrointestinal

- BRAFD BRAF V600E/V600K Somatic Mutation Analysis, Tumor
- EGFRS EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor
- PRKAF Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue
- FGFR2 FGFR2 (10q26.1) Rearrangement, FISH, Tissue
- H2GE HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue
- H2MT HER2 Amplification, Miscellaneous Tumor, FISH, Tissue
- HERGM HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual
- HERGN HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual, No Reflex
- KINET Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated
- METF MET (7q31), FISH, Tissue
- ML1HM MLH1 Hypermethylation Analysis, Tumor
- BRMLH MLH1 Hypermethylation and BRAF Mutation Analysis, Tumor
- IHC Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor
- TMSI Microsatellite Instability, Tumor

Genitourinary

- TFE3F Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue
- GCTF Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue
- H2UR HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue
- FUR0C UroVysion for Detection of Bladder Cancer, Urine
- NUT1F NUTM1 (15q14) Rearrangement, FISH, Tissue
- TFEFB Renal Cell Carcinoma, 6p21.1 (TFEB) Rearrangement, FISH, Tissue

Gynecology

Endometrial/Uterine Carcinoma

- ESTUF Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue
- ML1HM MLH1 Hypermethylation Analysis, Tumor

Ovarian Carcinoma

- XL2T FOXL2 Mutations Analysis, Next-Generation Sequencing, Tumor

Lower Anal-Genital Tract Carcinoma

- HPV6E Human Papillomavirus (HPV) High-Risk E6/E7, RNA In Situ Hybridization
- HPVHL Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization
- HPVHR Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization
- HPVLR Human Papillomavirus (HPV), Low-Risk, DNA In Situ Hybridization

Head and Neck

- FGF1F FGFR1 (8p11.2) Amplification, FISH, Tissue
- HPVHL Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization
- HPVHR Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization
- HPVLR Human Papillomavirus (HPV), Low-Risk, DNA In Situ Hybridization
- MAMLF MAML2 (11q21) Rearrangement, Mucoepidermoid Carcinoma (MEC), FISH, Tissue
- SGTF MYB (6q23) Rearrangement, FISH, Tissue

Melanoma

- BRAFB Cell-Free DNA BRAF V600, Blood
- BRAFD BRAF V600E/V600K Somatic Mutation Analysis, Tumor
- BRFKT BRAF/KIT Mutation Analysis, Next-Generation Sequencing, Tumor

Neuro-Oncology

- GLIOF 1p/19q Deletion in Gliomas, FISH, Tissue
- BRAFD BRAF V600E/V600K Somatic Mutation Analysis, Tumor
- CMAPT Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded
- GCTF Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue
- H33T Histone H3.3 Mutations, Next-Generation Sequencing, Tumor
- IDHT IDH1/IDH2 Mutations Analysis, Next-Generation Sequencing, Tumor
- MGMT MGMT Promoter Methylation, Tumor
- NONCP Neuro-Oncology Expanded Panel with Rearrangement, Tumor
- TERTT TERT Promoter Mutations, Next-Generation Sequencing, Tumor
- TP53 TP53 Mutation Analysis, Next-Generation Sequencing, Tumor

Pulmonary

- BRAFD BRAF V600E/V600K Somatic Mutation Analysis, Tumor
- EGFRS EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor

- EGFRW EGFR Targeted Mutation Analysis with ALK Reflex, Tumor
- FGF1F FGFR1 (8p11.2) Amplification, FISH, Tissue
- KRASP KRAS Somatic Mutation Analysis, Tumor
- LCAF Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue
- RETF Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue
- ROS1F Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue
- MESOF Mesothelioma, CDKN2A Fish, Tissue
- METF MET (7q31), FISH, Tissue

HEREDITARY ONCOLOGY TESTING

- BAP1Z BAP1-Tumor Predisposition Syndrome, BAP1 Full Gene Analysis, Varies
- BHDZ Birt-Hogg-Dube Syndrome, FLCN, Full Gene Analysis
- HBOCZ BRCA1/BRCA2 Genes, Full Gene Analysis
- BRGYP Hereditary Breast/Gynecologic Panel
- COMCP Hereditary Common Cancer Panel
- CDHZ Hereditary Diffuse Gastric Cancer Syndrome, CDH1, Full Gene Analysis
- ENDCP Hereditary Endocrine Cancer Panel
- XCP Hereditary Expanded Panel
- CRCGP Hereditary Gastrointestinal Cancer Panel
- LRCCZ Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome, FH, Full Gene Analysis
- PANCP Hereditary Pancreatic Cancer Panel
- HPGLP Hereditary Paraganglioma/Pheochromocytoma Pane
- PRS8P Hereditary Prostate Cancer Panel
- RENCP Hereditary Renal Cancer Panel
- THYRP Hereditary Thyroid Cancer Panel
- WILMP Hereditary Wilms Tumor Panel
- LYNCP Lynch Syndrome Panel
- NF1Z Neurofibromatosis Type 1, NF1, Full Gene Analysis
- PTNZ PTEN Hamartoma Tumor Syndrome, PTEN Full Gene Analysis
- STK1Z Peutz-Jeghers Syndrome, STK11, Full Gene Analysis
- RETZZ Multiple Endocrine Neoplasia Type 2 Syndrome, RET, Full Gene Analysis, Varies
- U1A1Q UDP-Glucuronosyltransferase 1A1 TA Repeat Genotype, UGT1A1
- UGTFG UDP-Glucuronosyl Transferase 1A1 (UGT1A1), Full Gene Sequencing
- VHLZZ Von Hippel Lindau Syndrome, VHL, Full Gene Analysis, Varies

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

**PRIMARY BODY FLUID TESTS
TESTS FOR DISEASE MONITORING
OR AIDING IN THE DIAGNOSIS**

Bone and Soft Tissue

IFG23 Intact Fibroblast Growth Factor 23, Serum

Breast

C2729 Breast Carcinoma-Associated Antigen, Serum

CA153 Cancer Antigen 15-3 (CA 15-3), Serum

Endocrine

Thyroid Cancer

CATLN Calcitonin, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash, Lymph Node

CATN Calcitonin, Serum

CEA Carcinoembryonic Antigen (CEA), Serum

TGMS Thyroglobulin Mass Spectrometry, Serum

TFNAB Thyroglobulin, Tumor Marker, Fine-Needle Aspiration Biopsy Needle Wash

HTGR Thyroglobulin, Tumor Marker Reflex, Serum

HTG2 Thyroglobulin, Tumor Marker, Serum

Neuroendocrine Tumors

CGAK Chromogranin A, Serum

GAST Gastrin, Serum

GLP Glucagon, Plasma

NSE Neuron-Specific Enolase, Serum

HPP Pancreatic Polypeptide, Plasma

VIP Vasoactive Intestinal Polypeptide, Plasma

Pituitary Tumors

ACTH Adrenocorticotropic Hormone, Plasma

APGH Alpha-Subunit Pituitary Tumor Marker, Serum

FSH Follicle-Stimulating Hormone (FSH), Serum

HGH Growth Hormone, Serum

LH Luteinizing Hormone (LH), Serum

MCRPL Macroprolactin, Serum

NSE Neuron-Specific Enolase (NSE), Serum

PLPMA Prolactin, Pituitary Macroadenoma, Serum

PRL Prolactin, Serum

Biogenic Amines

CATU Catecholamine Fractionation, Free, 24 Hour, Urine

CATP Catecholamine Fractionation, Free, Plasma

HVA Homovanillic Acid, 24 Hour, Urine

HVAR Homovanillic Acid, Random, Urine

HIAA 5-Hydroxyindoleacetic Acid, 24 Hour, Urine

METAF Metanephrines, Fractionated, 24 Hour, Urine

PMET Metanephrines, Fractionated, Free, Plasma

METRN Metanephrines, Fractionated, Random, Urine

SERU Serotonin, 24 Hour, Urine

SERWB Serotonin, Blood

VH Vanillylmandelic Acid and Homovanillic Acid, Random, Urine

VMA Vanillylmandelic Acid, 24 Hour, Urine

VMAR Vanillylmandelic Acid, Random, Urine

Gastrointestinal

L3AFP Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum

AFPPT Alpha-Fetoprotein (AFP), Peritoneal Fluid

AFP Alpha-Fetoprotein (AFP) Tumor Marker, Serum

AMLPC Amylase, Pancreatic Cyst Fluid

199PC Carbohydrate Antigen 19-9 (CA 19-9), Pancreatic Cyst Fluid

199PT Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid

CA19 Carbohydrate Antigen 19-9 (CA 19-9), Serum

CEAPC Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid

CEAPT Carcinoembryonic Antigen (CEA), Peritoneal Fluid

CEA Carcinoembryonic Antigen (CEA), Serum

CGAK Chromogranin A, Serum

DCP Des-Gamma-Carboxy Prothrombin, Serum

FOBT Fecal Occult Blood, Colorectal Cancer Screen, Qualitative, Immunochemical, Feces

GAST Gastrin, Serum

GLP Glucagon, Plasma

HCCGS Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum

HIAA 5-Hydroxyindoleacetic Acid, 24 Hour, Urine

NSE Neuron-Specific Enolase (NSE), Serum

HPP Pancreatic Polypeptide, Plasma

SERU Serotonin, 24 Hour, Urine

SERWB Serotonin, Blood

VIP Vasoactive Intestinal Polypeptide, Plasma

Genitourinary

AFPSF Alpha-Fetoprotein (AFP), Spinal Fluid

AFP Alpha-Fetoprotein (AFP) Tumor Marker, Serum

BHCG Beta-Human Chorionic Gonadotropin, Quantitative, Serum

BHSF Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid

CEASF Carcinoembryonic Antigen (CEA), Spinal Fluid

PSA Prostate-Specific Antigen (PSA) Diagnostic, Serum

SPSA Prostate-Specific Antigen (PSA) Screen, Serum

PHI11 Prostate Health Index Reflex, Serum

PSAFT Prostate-Specific Antigen (PSA), Total and Free, Serum

Gynecology

BHCG Beta-Human Chorionic Gonadotropin, Quantitative, Serum

CA25 Cancer Antigen 125 (CA 125), Serum

HE4 Human Epididymis Protein 4, Serum

INHA Inhibin A, Tumor Marker, Serum

INHAB Inhibin A and B, Tumor Marker, Serum

INHB Inhibin B, Serum

ROMA ROMA Score (Ovarian Malignancy Risk Algorithm), Serum

Pulmonary

PF199 Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid

PFCEA Carcinoembryonic Antigen (CEA), Pleural Fluid

NSE Neuron-Specific Enolase (NSE), Serum

**ADDITIONAL TESTS
(INDICATE TEST CODE AND NAME)**
